Nishchal Jain
Research Subjects
Nishchal Jain has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
Natrajan Bhavatharini
Diabetology, SRC Diabetes Care Center, Erode, IND
1 shared publication- Rajesh Jain
Jain hospital & research centre, Kanpur, India
1 shared publication Thangavel Saravanan
Nephrology, Abirami Kidney Care Private Limited, Erode, IND
1 shared publication- Veeraswamy Seshiah
Diabetes Care and Research Institute, Chennai, India
1 shared publication
Latest Publications
- Open Access
- 15 December 2022
- Published by Springer Nature in Cureus
- Vol. 14 (12) , e32573
Use of Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitor Remogliflozin and Possibility of Acute Kidney Injury in Type-2 Diabetes
The major trials, e.g., EMPA-REG OUTCOME, CANVAS, and CREDENCE, showed the renal and cardiovascular benefit of sodium-glucose transport protein 2 (SGLT2) inhibitors. The SGLT2 inhibitors, Empagliflozin, Dapagliflozin, and Canagliflozin, have shown no significant adverse renal effects. Still, our patients with type 2 diabetes on Remogliflozin, a type of SGLT2 inhibitor approved in India for the treatment of diabetes, seems to cause acute tubular necrosis as confirmed by clinical and pathological evidence in our study. The two critical findings in our research include a consistent rise in hs-CRP and a pathologist's biopsy report, excluding other causes. Therefore, we need sizeable cardiovascular-renal outcome trials to ascertain the safety of Remogliflozin in future studies.
- 15 December 2022
- Published by Springer Nature in Cureus
- Vol. 14 (12) , e32573
Open AccessUse of Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitor Remogliflozin and Possibility of Acute Kidney Injury in Type-2 Diabetes
The major trials, e.g., EMPA-REG OUTCOME, CANVAS, and CREDENCE, showed the renal and cardiovascular benefit of sodium-glucose transport protein 2 (SGLT2) inhibitors. The SGLT2 inhibitors, Empagliflozin, Dapagliflozin, and Canagliflozin, have shown no significant adverse renal effects. Still, our patients with type 2 diabetes on Remogliflozin, a type of SGLT2 inhibitor approved in India for the treatment of diabetes, seems to cause acute tubular necrosis as confirmed by clinical and pathological evidence in our study. The two critical findings in our research include a consistent rise in hs-CRP and a pathologist's biopsy report, excluding other causes. Therefore, we need sizeable cardiovascular-renal outcome trials to ascertain the safety of Remogliflozin in future studies.